ADVISORY, Apr. 16, 2015 (GLOBE NEWSWIRE) --
InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of people with spinal cord injuries, will visit the Nasdaq MarketSite in Times Square to mark the company’s uplisting to the Nasdaq Capital Market.
In honor of the occasion, Mark Perrin, CEO and Chairman, will ring the Opening Bell.
At the core of InVivo’s technology portfolio is the Neuro-Spinal Scaffold, a novel and proprietary biomaterial device implanted into the epicenter of a spinal cord injury to modulate the healing environment and serve as support for neuroregeneration. InVivo recently announced the first two patients have been enrolled in the ongoing pilot trial of the investigational Neuro-Spinal Scaffold for the treatment of traumatic acute spinal cord injuries with the goal of having the trial fully enrolled by the end of the year.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Friday, April 17, 2015 – 9:15 a.m. to 9:30 a.m. ET
InVivo Media Contacts:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV):
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.